Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 31, 2010

Achaogen Wins $64M BARDA Contract to Develop Antibiotic for Biothreats

Achaogen Wins $64M BARDA Contract to Develop Antibiotic for Biothreats

Firm’s lead compound ACHN-490 will be evaluated against organism causing bubonic plague. [ggw/Fotolia.com]

  • Antibiotics firm Achaogen has been awarded a potentially $64 million U.S. Biomedical Advanced Research and Development Authority (BARDA) contract to develop its lead clinical-stage antibiotic candidate ACHN-490 as a treatment for biothreat agents including the bubonic plague-causing bacterium Yersinia pestis and Francisella tularensis, which causes tularemia. BARDA's remit falls within the U.S. Department of Health and Human Services' Office of the Assistant Secretary for the Preparedness and Response.

    The contract includes $27 million in committed funding for the first two years, and subsequent option periods that, if completed, would take the total value of the award up to $64.5 million. Achaogen says the grant is the first to be awarded from BARDA's broad-spectrum antimicrobial initiative.

    Achaogen is focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. ACHN-490 is a next-generation aminoglycoside currently undergoing Phase II trials for the treatment of complicated urinary tract infections and acute pyelonephritis. Achaogen says it is also considering evaluating the drug for other indications including hospital-acquired pneumonia, ventilator-associated pneumonia, complicated intra-abdominal infections, and bloodstream infections.

    The firm claims its aminoglycoside compounds are designed to overcome known resistance mechanisms to existing aminoglycoside antibiotics. ACHN-490 is chemically engineered to retain activity against organisms resistant to carbeapenems, cephalosporins, fluoroquinolones, tetracyclines, and legacy aminoglycosides.

    The firm claims the BARDA contract will provide valuable data to support its development of ACHN-490 for the nonbiothreat indications. Achaogen raised $56 million in May through the completion of Series C round of financing.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »